This Top Stock Looks Too Cheap to Ignore

Oscar Health shares are up 53% year to date, but the article argues the stock remains undervalued given improving fundamentals and stronger operating leverage. Q1 2026 operating income reached $700 million, and full-year 2026 operating earnings are guided to $250 million-$450 million on revenue of about $19 billion. Membership has grown to 3.2 million paying members from just over 500,000 in Q1 2021, while ACA subsidy changes and utilization trends remain important catalysts.

Analysis

The market is not just re-rating OSCR on growth; it is implicitly pricing a regime shift from underwriting loss absorption to operating leverage. The key second-order effect is that improved pricing discipline in ACA can widen the moat: once an insurer proves it can adjust for utilization faster than peers, it can selectively win the best-risk cohorts while avoiding the worst, which tends to improve margins faster than membership growth alone. That creates a flywheel where scale is no longer just a top-line story but a claims-mix story.

The biggest miss in consensus is likely the timing asymmetry around subsidies versus utilization. Subsidy policy can change on a political cadence, but utilization normalization usually lags by quarters and is harder for the market to model in real time; that means the stock can stay volatile even as the underlying earnings power improves. If 2026 lands near the high end of guidance, the market may still underwrite it as a one-year anomaly rather than a new earnings base, especially because operating margin remains low in absolute terms and therefore looks fragile on a headline basis.

For competitors, the more interesting pressure point is not UNH-style scale in commercial/Medicare, but smaller ACA-focused carriers that lack enough data density to reprice as quickly. If Oscar keeps gaining share, those players face a bad mix of adverse selection and higher customer-acquisition costs, potentially forcing consolidation or retrenchment. The flip side is that UNH is less directly exposed here than the article implies; the real competitive damage is likely to be borne by regional exchange insurers and brokers rather than the diversified giants.

The contrarian risk is that the current move already discounts a clean normalization path, while healthcare utilization can re-accelerate if medical cost inflation persists or if Oscar’s book becomes too attractive to higher-utilization members. This is a months-to-years thesis, not a days-to-weeks trade: the near-term catalyst is any quarterly confirmation that margins hold as membership expands, while the main reversal trigger is a single update showing utilization or subsidy elasticity is less favorable than expected.

Key Decisions for Investors

• Long OSCR on pullbacks over the next 2-6 weeks; use a staged entry because the stock is likely to remain headline-sensitive. Target a 12-18 month horizon where the market begins capitalizing normalized operating income rather than treating 2026 as peak earnings. Risk/reward is attractive if the stock stays below a mid-single-digit EV/revenue multiple despite clear scale leverage.
• Buy OSCR call spreads 6-12 months out rather than outright calls to express upside while capping premium bleed. A bullish structure makes sense because the thesis needs proof of sustained utilization control, not just one quarter of strong earnings.
• Pair trade: long OSCR / short a basket of weaker ACA-exposed regional insurers or exchange-sensitive managed-care names if available in the book. The trade isolates the winner/loser dynamic from broad healthcare beta and monetizes Oscar’s faster repricing capability versus slower-moving competitors.
• Avoid using UNH as the short leg for the OSCR thesis; the better expression is against smaller exchange-focused carriers, since UNH’s earnings engine is diversified and less exposed to ACA-specific dynamics. This reduces the risk of being wrong for the wrong reason.
• Set a catalyst watch on the next two earnings prints: if operating income remains positive despite membership growth, add to the position; if utilization ticks back up, cut exposure quickly because the market will punish any sign that the 2026 margin inflection is not durable.